Cerenia
Active substance
ATC code
Species
Dogs and cats.
Indications
• For the treatment and prevention of nausea induced by chemotherapy.
• For the prevention of vomiting except that induced by motion sickness.
• For the treatment of vomiting, in combination with other supportive measures.
• For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
Cats• For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
• For the treatment of vomiting, in combination with other supportive measures.
Dose to be administered and administration route
For subcutaneous or intravenous use in dogs and cats.
Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days. Intravenous administration of Cerenia should be given as a single bolus without mixing the product with any other fluids.
In dogs, Cerenia can be used to treat or prevent vomiting either as tablets or as solution for injection administered once daily. Cerenia solution for injection may be administered for up to five days and Cerenia tablets for up to fourteen days.
To prevent vomiting, Cerenia solution for injection should be administered more than 1 hour in advance. The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.
Adverse reactions
Pain at injection site may occur when injected subcutaneously. In cats, moderate to severe response to injection is very commonly observed (in approximately one third of cats).
Anaphylactic type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) may occur in very rare cases.
Neurological disorders such as ataxia, convulsion/seizure or muscle tremor have been reported in very rare cases.
Lethargy has been reported in very rare cases.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Similar products
Showing 3 of 3 results
Cerenia
Cerenia
